GoOn Research and Development Project Wins Theseus-Mittelstand
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Transinsight has announced that the consortium formed with RESprotect, Antikorper-Online, and the Bioinformatics group of Prof. Dr. Michael Schroeder at TU Dresden, has won the Theseus-Mittelstand for R&D project GoOn. Over the next two years, the project -based on the results of Theseus One- will develop praxis-relevant semantic technologies for information handling in the biomedical domain.
The first goal of the project is to develop a specialized search engine to find antibody mentions in ordinary -not only scientific- texts. Antibodies play an important role in modern pharmaceutical research when, for example, labeling genes and proteins for optical particle tracking. Gene and protein names do not belong to a standardized nomenclature and developed rather organically in the years of their discovery.
Of the approximate 500,000 to 1,000,000 human proteins, each protein has an average of five synonyms and often hundreds of spelling variants. Furthermore, there are some proteins that share a common name and for which the context needs to be analyzed in order to classify them properly. Transinsight will work closely with antibody vendor Antikorper-Online on this area of the project to develop intelligent matching algorithms and new semantic advertisement technologies.
The second goal is the development of a semantic platform to elucidate gene interaction networks. Transinsight, RESprotect, and TU Dresden will work together to develop methods for the elucidation of BVDU, a highly promising drug against pancreatic cancer, currently in late-stage clinical trial. The end goal is to integrate all textual information with already known data to better understand the activity of the drug and optimize subsequent compounds.
The first goal of the project is to develop a specialized search engine to find antibody mentions in ordinary -not only scientific- texts. Antibodies play an important role in modern pharmaceutical research when, for example, labeling genes and proteins for optical particle tracking. Gene and protein names do not belong to a standardized nomenclature and developed rather organically in the years of their discovery.
Of the approximate 500,000 to 1,000,000 human proteins, each protein has an average of five synonyms and often hundreds of spelling variants. Furthermore, there are some proteins that share a common name and for which the context needs to be analyzed in order to classify them properly. Transinsight will work closely with antibody vendor Antikorper-Online on this area of the project to develop intelligent matching algorithms and new semantic advertisement technologies.
The second goal is the development of a semantic platform to elucidate gene interaction networks. Transinsight, RESprotect, and TU Dresden will work together to develop methods for the elucidation of BVDU, a highly promising drug against pancreatic cancer, currently in late-stage clinical trial. The end goal is to integrate all textual information with already known data to better understand the activity of the drug and optimize subsequent compounds.